...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Radiotherapy and oncology: Journal of the European Society for Therapeutic Radiology and Oncology >Preoperative hyperfractionated accelerated radiotherapy and radical surgery in advanced head and neck cancer: a prospective phase II study.
【24h】

Preoperative hyperfractionated accelerated radiotherapy and radical surgery in advanced head and neck cancer: a prospective phase II study.

机译：晚期头颈癌的术前超分割加速放射治疗和根治性手术：一项前瞻性II期研究。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND AND PURPOSE: To evaluate whether preoperative hyperfractionated accelerated radiotherapy (RT) combined with major radical surgery is feasible and successful in the treatment of advanced primary head and neck cancer. PATIENTS AND METHODS: Ninety four patients with histologically confirmed head and neck squamous cell cancer (HNSCC) in the oral cavity (41/96; 43%), supraglottis (14/96; 15%), glottis (5/96; 5%), oropharynx (16/96; 17%), nasal cavity/paranasal sinuses (8/96; 8%), nasopharynx (3/96; 3%), hypopharynx (7/96; 7%) and two (2%) with unknown primary tumour and large cervical lymph nodes entered into the study. 21/96 patients (22%) had stage II, 17/96 (18%) stage III and 58/96 patients (60%) stage IV disease. The patients received preoperative hyperfractionated RT 1.6 Gy twice a day, 5 days a week to a median tumour dose of 63 Gy with a planned break for 11 days (median) after the median dose of 37 Gy. Then, after a median of 27 days the patients underwent major radical surgery of the primary tumour and metastatic lymph nodes including reconstructions with pedicled or microvascular free flaps when indicated as a part of the scheduled therapy. 12/96 patients had only ipsilateral or bilateral neck dissections. RESULTS: After a median follow-up time of 37.2 mos 77/96 (80.2%) patients had complete locoregional control. All but 2 patients had complete histological remission after surgery. 40/96 pts were alive without disease, two of them after salvage surgery. 32/96 patients had relapsed; 15 had locoregional and 13 distant relapses, 4 patients relapsed both locoregionally and distantly. Fifty patients have died; 29 with locoregional and/or distant relapse, eight patients died of second malignancy, and 19 had intercurrent diseases. Disease-specific and overall survival at 3 years was 67.7 and 51%, respectively. Acute grade three mucosal reactions were common, but transient and tolerable. Late grade 3-4 adverse effects were few. CONCLUSIONS: Preoperative hyperfractionated accelerated RT can be successfully combined with major radical surgery in the treatment of HNSCC. The amount of serious late adverse effects was not increased.
机译：背景与目的：评估术前超分割加速放射治疗（RT）结合重大根治性手术在晚期原发性头颈癌治疗中是否可行且成功。患者和方法：94例经组织学证实口腔内头颈鳞状细胞癌（HNSCC）的患者（41/96; 43％），舌上肌（14/96; 15％），声门（5/96; 5％ ），口咽（16/96; 17％），鼻腔/鼻旁窦（8/96; 8％），鼻咽（3/96; 3％），下咽（7/96; 7％）和两个（2％ ）患有未知原发肿瘤且颈淋巴结较大的患者进入研究。 21/96名患者（22％）患有II期，17/96（18％）III期和58/96名患者（60％）IV期。患者每周5天每天两次接受术前超分割RT 1.6 Gy，中位肿瘤剂量为63 Gy，中位剂量为37 Gy后计划中断11天（中位）。然后，在中位数27天后，对患者进行原发性肿瘤和转移性淋巴结的重大根治性手术，包括作为有计划治疗的一部分的带蒂或微血管游离皮瓣的重建术。 12/96例患者只有同侧或双侧颈淋巴清扫术。结果：在中位随访时间为37.2 mos 77/96 mos（80.2％）之后，患者得到了完整的局部区域控制。除2例患者外，其余所有患者术后均完全组织学缓解。 40/96分还活着，没有疾病，其中两个在抢救手术后。 32/96例患者复发;局部复发15例，远处复发13例，局部和远处复发4例。五十名患者死亡; 29例发生局部和/或远处复发，8例患者死于第二次恶性肿瘤，19例患有并发疾病。 3年的疾病特异性生存率和总生存率分别为67.7和51％。急性三级粘膜反应很常见，但短暂且可耐受。晚期3-4级不良反应很少。结论：术前超分割加速放疗可以成功地与大型根治性手术联合治疗HNSCC。严重的后期不良反应没有增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号